Ultragenyx Pharmaceutical Statistics
Ultragenyx Pharmaceutical (RARE) Stock Statistics & Valuation Metrics
Total Valuation
Ultragenyx Pharmaceutical has a market cap or net worth of MXN 29.14B. The enterprise value is MXN 2.45B.
- Market Cap
- MXN 29.14B
- Enterprise Value
- MXN 2.45B
Share Statistics
Ultragenyx Pharmaceutical has 101,924,065 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 101,924,065
- Owned by Insiders
- 3.81%
- Owned by Institutions
- 44.12%
Financial Efficiency
Ultragenyx Pharmaceutical’s return on equity (ROE) is 7.19 and return on invested capital (ROIC) is -43.53%.
- Return on Equity (ROE)
- 7.19
- Return on Assets (ROA)
- -0.38
- Return on Invested Capital (ROIC)
- -43.53%
- Return on Capital Employed (ROCE)
- -0.47
- Revenue Per Employee
- 490.88K
- Profits Per Employee
- -419.40K
- Employee Count
- 1,371
- Asset Turnover
- 0.44
- Inventory Turnover
- 2.10
Valuation Ratios
The current PE Ratio of Ultragenyx Pharmaceutical is -3.16. Ultragenyx Pharmaceutical’s PEG ratio is -0.25.
- PE Ratio
- -3.16
- PS Ratio
- 2.22
- PB Ratio
- -4.46
- Price to FCF
- -3.66
- Price to Operating Cash Flow
- -3.84
- PEG Ratio
- -0.25
Income Statement
In the last 12 months, Ultragenyx Pharmaceutical had revenue of 673.00M and earned -575.00M in profits. Earnings per share was -5.83.
- Revenue
- 673.00M
- Gross Profit
- 564.00M
- Operating Income
- -535.00M
- Pretax Income
- -571.00M
- Net Income
- -575.00M
- EBITDA
- -474.00M
- Earnings Per Share (EPS)
- -5.83
Cash Flow
In the last 12 months, operating cash flow was -436.83M and capital expenditures -4.94M, giving a free cash flow of -441.77M billion.
- Operating Cash Flow
- -436.83M
- Free Cash Flow
- -441.77M
- Free Cash Flow per Share
- -4.33
Dividends & Yields
Ultragenyx Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -27.31%
- Earnings Yield
- -31.27%
Stock Price Statistics
- Beta
- 0.14
- 52-Week Price Change
- -68.43%
- 50-Day Moving Average
- 271.09
- 200-Day Moving Average
- 659.78
- Relative Strength Index (RSI)
- 1.24
- Average Volume (3m)
- 54
Important Dates
Ultragenyx Pharmaceutical upcoming earnings date is Feb 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Feb 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Ultragenyx Pharmaceutical as a current ratio of 2.48, with Debt / Equity ratio of -1595.00%
- Current Ratio
- 2.48
- Quick Ratio
- 2.34
- Debt to Market Cap
- 0.55
- Net Debt to EBITDA
- -1.78
- Interest Coverage Ratio
- -8.63
Taxes
In the past 12 months, Ultragenyx Pharmaceutical has paid 4.00M in taxes.
- Income Tax
- 4.00M
- Effective Tax Rate
- -0.01
Enterprise Valuation
Ultragenyx Pharmaceutical EV to EBITDA ratio is -6.36, with an EV/FCF ratio of -6.01.
- EV to Sales
- 3.64
- EV to EBITDA
- -6.36
- EV to Free Cash Flow
- -6.01
- EV to Operating Cash Flow
- -6.08
Balance Sheet
Ultragenyx Pharmaceutical has MXN 266.00M in cash and marketable securities with MXN 1.19B in debt, giving a net cash position of -MXN 920.00M billion.
- Cash & Marketable Securities
- MXN 266.00M
- Total Debt
- MXN 1.19B
- Net Cash
- -MXN 920.00M
- Net Cash Per Share
- -MXN 9.03
- Tangible Book Value Per Share
- -MXN 5.71
Margins
Gross margin is 82.88%, with operating margin of -64.11%, and net profit margin of -71.78%.
- Gross Margin
- 82.88%
- Operating Margin
- -64.11%
- Pretax Margin
- -72.60%
- Net Profit Margin
- -71.78%
- EBITDA Margin
- -57.15%
- EBIT Margin
- -61.78%
Analyst Forecast
The average price target for Ultragenyx Pharmaceutical is MXN 462.49, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- MXN 462.49
- Price Target Upside
- 80.66% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 20
- Revenue Growth Forecast
- 4.03%
- EPS Growth Forecast
- 21.40%
Scores
- Smart Score
- 5
- AI Score
- ―
